...
首页> 外文期刊>Brain: A journal of neurology >Evidence for label-retaining tumour-initiating cells in human glioblastoma.
【24h】

Evidence for label-retaining tumour-initiating cells in human glioblastoma.

机译:人胶质母细胞瘤中保留标签的肿瘤起始细胞的证据。

获取原文
获取原文并翻译 | 示例
           

摘要

Individual tumour cells display diverse functional behaviours in terms of proliferation rate, cell-cell interactions, metastatic potential and sensitivity to therapy. Moreover, sequencing studies have demonstrated surprising levels of genetic diversity between individual patient tumours of the same type. Tumour heterogeneity presents a significant therapeutic challenge as diverse cell types within a tumour can respond differently to therapies, and inter-patient heterogeneity may prevent the development of general treatments for cancer. One strategy that may help overcome tumour heterogeneity is the identification of tumour sub-populations that drive specific disease pathologies for the development of therapies targeting these clinically relevant sub-populations. Here, we have identified a dye-retaining brain tumour population that displays all the hallmarks of a tumour-initiating sub-population. Using a limiting dilution transplantation assay in immunocompromised mice, label-retaining brain tumour cells display elevated tumour-initiation properties relative to the bulk population. Importantly, tumours generated from these label-retaining cells exhibit all the pathological features of the primary disease. Together, these findings confirm dye-retaining brain tumour cells exhibit tumour-initiation ability and are therefore viable targets for the development of therapeutics targeting this sub-population.
机译:各个肿瘤细胞在增殖率,细胞间相互作用,转移潜力和对治疗的敏感性方面表现出多种功能行为。而且,测序研究已经证明了相同类型的单个患者肿瘤之间令人惊讶的遗传多样性水平。肿瘤异质性提出了重大的治疗挑战,因为肿瘤内的多种细胞类型可能对疗法产生不同的反应,而患者间异质性可能会阻止癌症常规疗法的发展。一种可能有助于克服肿瘤异质性的策略是鉴定肿瘤亚群,这些亚群驱动特定疾病病理,从而发展针对这些临床相关亚群的疗法。在这里,我们确定了一种保留染料的脑肿瘤种群,该种群显示出引发肿瘤的亚群的所有特征。在免疫功能低下的小鼠中使用有限稀释移植试验,保留标签的脑肿瘤细胞相对于总体种群具有更高的肿瘤起始特性。重要的是,由这些保留标签的细胞产生的肿瘤表现出原发疾病的所有病理特征。总之,这些发现证实了保留染料的脑肿瘤细胞具有肿瘤起始能力,因此是靶向该亚群的治疗药物开发的可行靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号